• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.50% Nasdaq Up0.51%

    Progenics Pharmaceuticals, Inc. (PGNX)

    -NasdaqGS
    5.87 Up 0.32(5.68%) 2:16PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Progenics Pharmaceuticals, Inc.
    777 Old Saw Mill River Road
    Tarrytown, NY 10591
    United States - Map
    Phone: 914-789-2800
    Fax: 914-789-2817
    Website: http://www.progenics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:57

    Business Summary 

    Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. It also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. In addition, the company develops Relistor-oral that has completed Phase III testing for the treatment of OIC. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Progenics Pharmaceuticals, Inc.

    Corporate Governance 
    Progenics Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2015 is 2. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 1; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Mark R. Baker J.D., 60
    Chief Exec. Officer, Director and Member of Science & Strategy Committee
    850.00K0.00
    Dr. Paul J. Maddon M.D., Ph.D., 55
    Founder, Vice Chairman and Member of Science & Strategy Committee
    N/AN/A
    Mr. Angelo William Lovallo Jr., 50
    Principal Financial Officer, Principal Accounting Officer, VP of Fin. and Treasurer
    393.00K0.00
    Dr. Robert J. Israel M.D., 58
    Exec. VP of Innovation
    619.00K42.00K
    Mr. David E. Martin , 60
    Gen. Counsel
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders